Lead Product(s) : Talabostat Mesylate,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
BioXcel Receives FDA Fast Track Designation for BXCL701 in Prostate Cancer
Details : BXCL701 (talabostat mesylate) is an oral small molecule DPP inhibitor under investigation for small cell neuroendocrine prostate cancer treatment.
Product Name : BXCL701
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 02, 2024
Lead Product(s) : Talabostat Mesylate,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Talabostat Mesylate,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
BioXcel Completes Enrollment in Safety Portion Of Phase 2 Trial for BXCL701 and KEYTRUDA®
Details : BXCL701 (talabostat mesylate) is an oral innate immune activator evaluated in phase 2 clinical trials in combination with Keytruda for treating metastatic pancreatic ductal adenocarcinoma.
Product Name : BXCL701
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 02, 2024
Lead Product(s) : Talabostat Mesylate,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Talabostat Mesylate,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BXCL701 is an investigational, oral innate immune activator designed to initiate inflammation in the tumor microenvironment. BXCL701 is currently being developed as a potential therapy for the treatment of aggressive forms of prostate cancer and advanced...
Product Name : BXCL701
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 01, 2023
Lead Product(s) : Talabostat Mesylate,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Talabostat Mesylate,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BXCL701 (talabostat mesylate) is an investigational, oral innate immune activator designed to initiate inflammation in the tumor microenvironment. it is currently being developed for combination with (pembrolizumab) in patients with small cell neuroendoc...
Product Name : BXCL701
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 10, 2023
Lead Product(s) : Talabostat Mesylate,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Talabostat Mesylate,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BXCL701 (talabostat mesylate) is an investigational, oral innate immune activator designed to initiate inflammation in the tumor microenvironment. it is currently being developed for combination with (pembrolizumab) in patients with mCRPC of Adenocarcino...
Product Name : BXCL701
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 11, 2023
Lead Product(s) : Talabostat Mesylate,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Talabostat Mesylate,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BXCL701 (talabostat mesylate) is an investigational, oral innate immune activator designed to initiate inflammation in the tumor microenvironment. BXCL701 is currently being developed for aggressive forms of prostate cancer and advanced solid tumors.
Product Name : BXCL701
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 02, 2023
Lead Product(s) : Talabostat Mesylate,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Talabostat Mesylate,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BXCL701 (talabostat mesylate) is an investigational, oral innate immune activator designed to initiate inflammation in the tumor microenvironment. BXCL701 is currently being developed for aggressive forms of prostate cancer and advanced solid tumors.
Product Name : BXCL701
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 13, 2023
Lead Product(s) : Talabostat Mesylate,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Talabostat Mesylate,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BXCL701 is an investigational orally administered innate immune activator designed to initiate inflammation in tumor microenvironment, is being evaluated in combination with KEYTRUDA in an ongoing Phase 2 trial in mCRPC patients with either adenocarcinom...
Product Name : BXCL701
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 19, 2022
Lead Product(s) : Talabostat Mesylate,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Talabostat Mesylate,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BXCL701 (talabostat mesylate), investigational orally administered innate immune activator plus KEYTRUDA (pembrolizumab) demonstrates encouraging composite response rates in SCNC (33%) and adenocarcinoma (21%) cohorts.
Product Name : BXCL701
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 14, 2022
Lead Product(s) : Talabostat Mesylate,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Talabostat Mesylate,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BXCL701 plus KEYTRUDA® (pembrolizumab) demonstrates encouraging anti-tumor activity in heavily pre-treated mCRPC patients with adenocarcinoma. BXCL701 is orally administered innate immune activator designed to initiate inflammation in tumor microenviron...
Product Name : BXCL701
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 15, 2021
Lead Product(s) : Talabostat Mesylate,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable